Ofatumumab

奥法妥木单抗

Report date: 2024/06/03 10:38:39

Base Information

Drug NameOfatumumab
Drug Alias Name奥伐单抗Anti-CD20 monoclonal antibody奥法木单抗奥法单抗Arzerra +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsPemphigusMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis +[12] 
Global Approved IndicationsMultiple Sclerosis, Relapsing-RemittingLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaMultiple Sclerosis, Relapsing-Remitting
Original Approved Country/TerritoryUnited States
Original Approved Date2009/10/26
Country/TerritoryCzechiaBelgiumBulgaria +[51] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenmab A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Ireland LtdGlaxosmithkline PlcNovartis Pharma Ag +[4] 
Inactive CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer CenterGlaxo Group Ltd +[9] 
Active IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsPemphigusArthritis, RheumatoidWaldenstrom Macroglobulinemia +[9] 

Other Information

ATC CodeL01XC10
Related LinksWikipediaDrugBankKEGG